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Gene expression from bacterial artiﬁcial chromosome (BAC) clones has been demonstrated to facilitate physiologically relevant
levels compared to viral and nonviral cDNA vectors. BACs are large enough to transfer intact genes in their native chromosomal
setting together with ﬂanking regulatory elements to provide all the signals for correct spatiotemporal gene expression. Until
recently, the use of BACs for functional studies has been limited because their large size has inherently presented a major
obstacle for introducing modiﬁcations using conventional genetic engineering strategies. The development of in vivo homologous
recombination strategies based on recombineering in E. coli has helped resolve this problem by enabling facile engineering of high
molecular weight BAC DNA without dependence on suitably placed restriction enzymes or cloning steps. These techniques have
considerably expanded the possibilities for studying functional genetics using BACs in vitro and in vivo.
1.Introduction
The information generated from the Genome Projects will
be of the greatest value if it can be converted into functional
data, particularly if this increases our understanding of
normal gene function and allows strategies to be developed
for prevention and treatment of human disease. Likewise,
the output of genetic variants of human disease uncovered
by the International HapMap Project [1]r e q u i r e se ﬀective
toolstoaccuratelytranslatethisgrowingknowledgetomodel
systems for functional studies.
Bacterial artiﬁcial chromosomes, or BACs, are fertility-
(F-) factor-based plasmid vectors that replicate stably in low
copy number [2, 3]. Because of their large insert capacity,
BACs can carry complete genes containing ﬂanking distant
regulatory DNA that provide signals for correct spatio-
temporal gene expression [4–9]. As the average size of the
protein-coding genes annotated in Human Genome Project
is 27kb [10], most of the genes are well within the cloning
capacity of BAC vectors. Thus, BACs carrying full-length
genes in their natural chromosomal setting is becoming
an attractive resource for studying genome structure and
function,representinganexcitingalternativetoconventional
vector systems.
However, until about a decade ago, the large size of BACs
has presented major hurdle for their precise manipulation
to introduce speciﬁc changes such as mutations, reporter
genes, and markers for functional studies in the mammalian
environment [11–13]. To address this problem, a number of
techniques were developed in the late 1990s that were based
on homologous recombination pathways, which meant
they were not limited by the size of a BAC, permitting
much more ﬂexible engineering compared to conventional
genetic engineering using restriction enzymes or site-speciﬁc
recombination methods. One of these is recombineering
(recombination-mediated genetic engineering [14]), which
was adapted from bacteriophage where the recombination
geneswerecarefullydelineatedandmovedtomobileplasmid
systems that were transferable to host E. coli strains.
Recombineering technology has gradually evolved into a
powerful new approach to studying genetic function using
genes in their natural genomic context that were widely2 Journal of Biomedicine and Biotechnology
Table 1: Comparing conventional BAC modiﬁcation strategies with recombineering.
Conventional strategies Recombineering
BAC Modiﬁcation
Strategies
Homologous recombination:
RecBCD and RecF pathways
RecE pathway: RecE, RecT
(+Gam)
Site-speciﬁc integration:
Integrases of diﬀerent
pathways (Cre, Flp)
Lambda Red pathway: Exo,
Beta, Gam
Flexibility
Require pre-engineered or
existing speciﬁc sites: Chi sites,
recombinase attachment sites
Sequence independent, but
need prior knowledge of
target sequence
Homology
requirement
Long homology of ∼1kbis
required for eﬃcient
homologous recombination
As short as 40bp of homology
is suﬃcient
Versatility May require speciﬁc strain
backgrounds to work
Mobile systems can be easily
transferred to and adapted for
use in a wide range of strains
and species
Eﬃciency and
facileness
Low eﬃciency for
homologous recombination
At least 50-fold higher than
traditional homologous
recombination
Labourious and lengthy Can be done in days
available from clones in BAC libraries [15]. Furthermore
recombineering have been further improved by combin-
ing with other genetic engineering methods such as site-
speciﬁc integration systems for more sophisticated BAC
manipulations [16–19]. This paper will focus on the rise of
recombineering as the major homologous recombination-
mediated approach for BAC modiﬁcations, as well as its
novel applications and future prospects in the art of genetic
tinkering.
2. BACModiﬁcations Using Recombineering
Recombineering is deﬁned as homologous recombination
mediated by phage-based recombination systems, which
include the Rac prophage-derived RecE pathway and also the
E. coli λ phage Red pathway (Table 1)( r e v i e w e db yC o p e l a n d
et al. [14]). The RecE pathway principally involves RecE and
RecTproteins,whiletheλRedpathwayismediatedbyitsExo
and Beta proteins (reviewed by Court et al. [20]).
The key feature of recombineering strategies is that it
is independent of E. coli endogenous homologous recombi-
nation functions, and it therefore, can be transferred using
mobile plasmids into hosts that are recombination deﬁcient
(e.g., RecA background) to introduce recombination pro-
ﬁciency transiently [21–24]. Transient systems that expose
the target DNA for only a short time to the recombination
enzymes provide the added beneﬁt of facilitating the stable
modiﬁcation of DNA substrates that are traditionally prone
to rearrangements due to recombination, for example, BACs
containing repetitive DNA [25].
Recombineering can be used for many modes of BAC
mutagenesis as well as cloning, based on the design of the
targetingsubstrate(Figure 1).Thetargetsitecanbeeitheron
a resident plasmid, chromosomal region, or even exogenous
source of DNA [26], while the incoming targeting substrate
can either be a linear dsDNA [21, 22] or single-stranded
oligonucleotides [27, 28]. As the required length of shared
homology for eﬃcient recombineering is typically only 40–
50bp [22], targeting substrates can be easily produced by
standard PCR procedures or oligo synthesis.
The ability of recombineering to mediate recombination
with open-ended linear dsDNA is made possible by the
additional expression of λ Gamma (Gam) protein to the
Red [21, 29] and RecE pathways [22, 23]. Gam inhibits the
exonuclease activity of RecBCD and spares linear dsDNA
from degradation, allowing it to recombine to its target
[30, 31]. With coordinated control of Gam expression,
BACs can be modiﬁed in RecBCD+ host strains with linear
dsDNAwhileavoiding thedeleteriouseﬀectsofRecBCDnull
mutation and constitutive Gam expression on cell viability
[23, 31, 32]. On the other hand, recombineering with single-
stranded oligos requires only the function of Beta [27]o r
RecT [33] and is only slightly aﬀected by RecBCD in the
absence of Gam expression [27].
By incorporating homologous sequences at the two ends
ofthetargetingsubstratetocorrespondtosequencesﬂanking
a target site, recombination at the two homologous sites can
eﬀectively insert the targeting substrate in place of the target
site (Figure 1(a)). This is a straightforward one-step strategy
to delete a gene of interest while introducing a foreign
sequence, usually a selectable antibiotic marker gene or a
transgene of interest. If no native DNA needs to be removed,
newsequencescanalsobeintroducedbydesigningtheﬂank-
ing homology arms of the targeting substrate to correspond
to the target site without any gap in between (Figure 1(b)).
Operational sites such as antibiotic marker and recombinase
recognition sites (loxP, FRT, etc.) can be integrated this way
with minimal disruption to the target DNA.Journal of Biomedicine and Biotechnology 3
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Figure 1: General applications of recombineering in BAC modiﬁcations. Recombineering is applicable in various mutagenesis strategies,
depending on the design and nature of the targeting substrate and target site; see text for more details. Stippled boxes denote homologous
sequences for recombination. (a) Gene replacement. Recombineering can be employed to replace a target site with any sequence of interest.
(b)Insertion.DNAcanalsobeintroducedbyrecombineeringwithoutremovinganyoftheexistingsequence.(c)Selection/counterselection.
Recombineering can mediate subtle modiﬁcations such as nucleotide substitutions via two rounds of recombinations, by ﬁrst introducing a
selectable cassette followed by replacement of the cassette with the modiﬁed version of the target site. (d) Gap repair cloning. A target site of
interest can be cloned from a fragment or plasmid into a linearised vector in vivo by recombineering, through recombination between the
ends of the cloning vector and target site.
Besides the removal, insertion, or replacement of large
segments,subtlemodiﬁcationswithnooperationalsequence
introduced can be achieved by the selection/counter-
selection strategy [22]( Figure 1(c)). This two-round recom-
bineering strategy ﬁrst involves the replacement of the target
site with a selectable cassette, of which the presence can be
selected for and against. The cassette is then subsequently
replaced by a modiﬁed version of the target site, and the
correct recombinants are recovered by selecting against
the selectable cassette. Popular options of counter-selection
markers include sacB [22], rpsL [34], I-SceI endonuclease
[35], as well as markers that can both be selectable for
and against including galK [36], thyA [37], and tolC [38].
Subtle mutations such as nucleotide substitution can also
be generated in single-step recombineering with ss-oligo as
targeting substrate; however, screening of colonies will be
required to detect correct recombinants [24].
One remarkable use of recombineering is the eﬀective
gap repair cloning of any target site of interest, which is
similar to transformation-associated recombination (TAR)
cloning in recombination-proﬁcient yeast [39]. This is done
by constructing a cloning vector with homology arms corre-
sponding to the target site, which is joined to form circular
closed plasmid following recombination (Figure 1(d)). The
recombinant plasmid vector can then be easily retrieved
with plasmid puriﬁcation protocols. This in vivo cloning
application is a powerful method as it can facilitate retrieval
of a target site from various origins, including linear dsDNA
cassette, resident plasmid, chromosome, and even genes
from a complex mixture of total genomic DNA [26].4 Journal of Biomedicine and Biotechnology
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Figure 2: Evolution of recombineering as a major modiﬁcation strategy for BACs. The evolution of homologous recombination over time
since the 1980s is depicted in green (conventional homologous recombination) and red boxes (recombineering), respectively, while major
applications of recombineering are depicted in orange boxes. Conventional homologous recombination was the main approach for BAC
modiﬁcations between 1980s and early 1990s ((a)–(c)), alongside early recombineering techniques mediated by E. coli strains carrying
activated λ or Rac recombination functions ((d)-(e)). Following the establishment of deﬁned recombineering systems in late 1990’s (f),
recombineering emerged as the favourable method over conventional homologous recombination, and technologies for recombineering
rapidly expanded in the next few years ((g)-(h)). Recombineering has, thereafter, been adopted for use in a wide range of biological
applications ((i)–(m)). See text for details.
However, due to the diﬃculty of rescuing large genes from
totalDNA,sofar,thistechniquehasnotbeenusedtodirectly
clone genomic fragments into BAC clones.
3. Emergence of Recombineering as an Ideal
BAC Modiﬁcation Technique
To deal with the large size that is inherent of BACs,
several novel methods were tested based on site-speciﬁc
recombination systems, including the P1-derived Cre-lox
[40, 41], the baker’s yeast Saccharomyces cerevisiae Flp-
FRT machineries [42], as well as traditional homologous
recombination methods, but they have mostly had limited
success (Table 1). First, they require the ready presence
or introduction of strategically placed recombination sites
on both the donor and recipient DNA molecules, which
will be left as “footprints” in the modiﬁed constructs [43,
44]. Additionally, the eﬀects of pseudoattachment sites in
a system, if any, must be investigated ahead in order to
eliminate retargeting to unwanted sites [19]. Furthermore,
the reversible reactions of some integrases (e.g., Cre [45]a n d
FLP [46]) must be taken into consideration as the frequency
of correct recombination could be reduced. Nevertheless the
precision, and in some cases reversibility, oﬀered by site-
speciﬁc integration systems are very useful properties for
ﬂexiblegeneticengineering.Hence,recombineeringandsite-
speciﬁc integration systems can complement each other in a
synergistic manner as recombineering can accurately posi-
tion integrase attachment sites in any location of choice [47].
In E. coli, the 5 G-C-T-G-G-T-G-G3 octamer, known as
Chi (crossover hotspot instigator), is a hotspot that stimu-
lates recombination close to this sequence via the recBCD
pathway [48]. A Chi-based strategy was used to target
fusion of the green ﬂuorescent protein reporter gene into a
zebraﬁsh GATA-2 BAC, in which the authors used a non-
replicative targeting linear construct containing properly
oriented Chi sites located near each end to stimulate homol-
ogous recombination [6]. The resulting GATA-2 promoterJournal of Biomedicine and Biotechnology 5
GFP-fusion BAC displayed the correct expression pattern of
the reporter gene in developing skin EVL cells, neurons, and
circulating blood cells [6]. Although this strategy simpliﬁed
the targeting and identiﬁcation of recombinant BACs, like
site-speciﬁc integration systems, its major limitation is the
time-consumingstepofgeneratingtargetingDNAﬂankedby
Chi sites (Table 1).
BACs are generally maintained in the E. coli host strain
DH10B because it has many suitable qualities, including per-
missiveforcloning ofmethylatedeukaryoticDNA,enhanced
transformation of very large DNA, high transformation eﬃ-
ciency,andtheabilitytoyieldhigh-qualityDNAduringDNA
isolation [3, 49]. However, because this host is recombina-
tion deﬁcient (recA-), exploiting its intrinsic homologous
recombination mechanism for BAC manipulation had been
challenging. Early homologous recombination strategies for
BACs were thus developed in other E. coli mutant strains.
One of the earliest methods using the RecBCD pathway of E.
coli was described by O’Connor et al. [50]( Figure 2(a)). The
authors used a combination of complex steps of homologous
and site-speciﬁc recombination in E. coli to recombine
overlapping regions of large genomic fragments carrying the
Drosophila ultrabithorax (ubx) gene, a technique they called
“chromosomal building” [50]( Figure 2(a)).
Approximately a decade later, Messerle et al. [51] used
this rather tedious technique to mutagenize the mouse
cytomegalovirus (mCMV) genome, contained in a 230kb
BAC and to generate virus mutants. Soon after, this tech-
nique was extended into E. coli DH10B by transiently
supplying the recA gene [52]. The lacZ gene was fused in-
frame with the promoter of the RU49 gene located on a
131kb BAC and shown to correctly express in a spatio-
temporal fashion in mice [52].
The recombination potential of the RecF pathway that
operates in recBC sbcBC mutant strains has also been applied
to construct plasmids by in vivo cloning a DNA fragment
into a linearised vector via the gap repair approach [53, 54]
(Figure 2(b)). Similarly, the endogenous RecF pathway of E.
coli BJ5183 was used to clone and mutagenize the complete
adenovirus genome, simplifying the process of generating
adenovirus variants [55, 56]( Figure 2(c)). Curiously, low-
eﬃciency gap repair activity was reported in the RecA- E. coli
strain DH5α but the pathway(s) mediating the homologous
recombinationwasnotexplainedandthisresulthasnotbeen
veriﬁed by other publications since [57].
These studies highlighted the exciting use of endogenous
homologous recombination pathways directly in E. coli to
generateprecisegenemodiﬁcations,buttechnicallimitations
exist for these strategies (Table 1). Firstly, the high levels
of background rearrangements observed in some cases [6,
51, 52] was a concern. Moreover, traditional recombination
technologies typically require long homologous sequences of
about 1kb for eﬃcient recombination rate [54], which is too
long to accurately synthesise with standard PCR procedures.
As these RecA-dependent strategies only work in strains
with speciﬁc mutant backgrounds (e.g., recBC sbcB for RecF
pathway [53]a n drecA for transient RecA [52]), they are
either not transferable to general strains or BACs will need
to be shuttled from the speciﬁc strain out after modiﬁcation.
It became clear that although it was possible to engineer
changestolargeBACsusingvariousestablishedconventional
strategies in E. coli, a straightforward, eﬃcient, and stable
BAC manipulation technique in E. coli that leaves no
modiﬁcation footprints behind would be more favourable.
The quest for such a tool resulted in development of recom-
bineering technology [14]. Recombineering is advantageous
over conventional BAC modiﬁcation strategies in several
aspects (Table 1). Most importantly, recombineering facil-
itates the introduction of almost unlimited modiﬁcations
to BACs with very high eﬃciency compared to traditional
homologous recombination [21, 22]. Virtually, any position
onaBACcanbetargetedaslongasitssequenceisknownand
the required homology size (∼40bp) [22] is short enough
to be synthesised in vitro. In addition to its tremendous
target ﬂexibility, the development of mobile recombineering
systems [21–23, 29], where the recombination function
can be introduced into any host via a plasmid, greatly
enhances its scope of application in various bacterial strains
(Figure 2(f)). The simplicity of recombineering strategies
also translates to technical ease, while more sophisticated
recombineering strategies can introduce clean mutagenesis
without any footprints as site-speciﬁc recombination does.
4. Evolutionof Recombineering Technologies
Earlyresearchthatledtothedevelopmentofrecombineering
(Figure 2) can be traced back to the exploitation of E. coli
mutant strains that carry functional phage recombination
mechanisms derived from lambda and the RecE/RecT genes
from the Rac prophage (Figures 2(d)-2(e)) [58, 59]. How-
ever, it was not until the advent of regulatable and deﬁned
recombineering systems in late 1990s (Figure 2(f)) that the
technologies and potential of recombineering became well
established.
4.1. Gene Replacement/Insertion/Deletion. E. coli K12 strains
carrying the defective Rac prophage [58] has been utilised
for mutagenesis of E. coli chromosomes and plasmids
since the 1980s. The recombination proﬁciency in this
strain was eventually discovered to be attributed to sbcA
mutation which causes overexpression of the RecE pathway
[60], leading to recombination activity that phenotypically
suppresses the recBC mutations [61]. In 1987, Kiel et al.
constructed mutants of K12 strains by exchanging the target
chromosomal segment with a mutant gene carried by an
incoming plasmid, utilising the RecE pathway endogenous
to K12 [62]( Figure 2(d)). About a decade later, the potential
of recombineering for gene replacement was tapped into
by inducible expression of λ Red genes [21]a n dR e c E T
[22]( Figure 2(f)). Soon after, the λ Red-mediated recom-
bineering was used to construct a series of chromosomal
gene replacement strains, using PCR cassettes as targeting
substrates [63, 64].
4.2. Gap Repair Cloning. Similarly the gap-repair ability of
a recBC sbcA strain, where the RecE pathway operates, was
used to directly clone PCR products in vivo by Oliner et al.6 Journal of Biomedicine and Biotechnology
[59]( Figure 2(e)). Kawaguchi and Kuramitsu [65] followed
by adapting this approach to describe a cloning method
in a recBC sbcA strain that they designated “homologous
ligation”, with homology length as short as 20bp. The power
of recombineering in gap repair cloning was eventually
demonstrated by Zhang et al. [26]( Figure 2(e)), who
conducted highly eﬃcient in vivo subcloning in E. coli using
a concept similar to TAR cloning in yeast (see above) [39].
4.3. Deﬁned Recombineering Systems. The milestone in
recombineering development is the establishment of deﬁned
recombineering systems, which consist of RecE/RecT or λ
RedExo/Beta underinduciblepromotersfortightexpression
regulation (Figure 2(f)). Despite not being involved in the
actual recombination reaction, λ Red Gam is incorporated
into these systems to facilitate the use of open-ended linear
dsDNA as targeting substrates by protecting them from
recBCD degradation [21–23]( Figure 2(f)). These plasmid-
based systems permit tight regulation of the recombineering
genes, thereby limiting unwanted recombination events, and
also allow transfer of the systems for use in various strains
and even species (Table 1).
As the λ prophage carries all the necessary Red genes for
recombineering, a system based on defective λ prophage was
developed [64]( Figure 2(f)). Among the key features of this
system is the temperature-sensitive regulation of Red genes
based on cI repressor and also its mobility to other E. coli
strainsbyP1cotransduction.Howevertheeliminationofthis
defective prophage-based system requires additional eﬀort,
as a speciﬁc recombination reaction to replace the prophage
with selectable cassette is necessary [64].
Because of the incompatibility of the defective prophage
system with certain BACs [24], a tractable mini-λ system
was subsequently developed [24]( Figure 2(f)). This mini-λ
is deleted for lethal genes and can be easily excised out via
λ attachment sites. The reported recombination eﬃciency
was so high that direct screening of recombinant clones
without selection was feasible [24]. The frequency obtained
was 1 in 61 for direct nucleotide substitution by ss-oligo
recombineering as conﬁrmed by sequencing [24].
Next, a unique hybrid recombineering system that brings
together RecA and Red-mediated homologous recombina-
tion techniques was developed [66]( Figure 2(f)), following
the establishment of RecA-mediated recombination method
in neuroscience research [67, 68]. In this method, the
RecA-dependent technique was integrated with the λ Red
recombineering for seamless modiﬁcation of BACs. This
hybrid recombineering utilizes Red recombineering to insert
(“pop-in”) a DNA sequence of interest alongside marker
genes and RecA on a selectable cassette, followed by RecA
expression from the cassette to excise (“pop-out”) vector
sequences [66].
In another work, RecA was incorporated into a diﬀerent
λ Red recombineering system but not for its recombination
function [69]( Figure 2(f)). Instead, transient RecA expres-
sion was induced to increase survival rate of transformants,
leading to about 4- to 5-fold improvement in transformation
eﬃciencyandconsequentlyupto8-foldincreaseinrecombi-
nation frequency [69]. While not experimentally proven yet,
transient expression of RecA might be beneﬁcial to RecET
recombineering as it does to λ Red recombineering.
4.4. Selection/Counterselection Mutagenesis. Although the
one-steprecombineeringstrategyformutagenesisiseasyand
straight forward, often operational sequences like antibiotic
resistance gene will be left behind. In order to create
“clean” mutation without the potential disruptive eﬀects of
integrated operational sequences, a counterselection strategy
is employed (see Figure 1(c)). While antibiotic resistance
genes are generally the choice for selection markers, the
option for counter selection is constantly being explored
(Figure 2(g)). One of the earliest counter-selection genes
used in recombineering is sacB [22]( Figure 2(g)), which
enables counterselection by sucrose addition. Spontaneous
mutations in sacB that ablate sucrose sensitivity do arise
during the course of recombination, however [22], so
careful screening of recombinant clones is necessary for the
conﬁrmationofdesiredgenotype.Anothercounter-selection
marker used is the wild-type rpsL+a l l e l e( Figure 2(g)),
which was ﬁrst used by Imam et al. [34] for PAC modiﬁ-
cations in streptomycin-resistant rpsL− DH10B. However,
rearrangements on the clones were observed, warranting
the need for additional recombinant screening. One novel
counterselection strategy is the use of the highly speciﬁc
I-SceIe n d o n u c l e a s e[ 35]( Figure 2(g)), by expressing it to
cleave the 18bp I-SceI recognition site present only in
nonrecombinant clones. Unfortunately, the observation of
high false positives, due to background deletion of I-SceI
gene and recircularisation events, required extra eﬀort in
ensuringhighI-SceIexpressionlevelandinvitrolinearisation
of recombinant BACs before electroporation [35].
Compared to counter-selection markers that need to
be used in conjunction with another selection marker,
marker genes that serve the dual purpose of selection and
counter-selection are more convenient to use. One such
example is galK (Figure 2(g)), which is adapted for use
in recombineering by Warming et al. in ΔgalK strains
[36]. By having only one marker gene in the selectable
cassette, selection/counter-selection is easily accomplished
by simply alternating the substrate (galactose for selection,
2-deoxy-galactose for counter-selection) during the two-step
recombineering [36]. Nevertheless, low level of spontaneous
deletions spanning galK was observed although they were
concluded to be due to background reaction in DH10B [36].
Another example of dual-selectable marker gene for use
in recombineering is thyA [37]( Figure 2(g)), which can be
selected for in the absence of thymine, and against by the
addition of thymine and trimethoprim in minimal growth
media. As this selection method must be performed in
thyA null mutant background, it might be restricted for
use in general strains or require additional thyA knockout
step for adaptive use. Nevertheless, it is a highly eﬃcient
approach that gives over 90% of accurate selection frequency
with low levels of backgrounds up to 0.08% [37]. More
recently, the tolC gene which encodes an outer membrane
protein (Figure 2(g)) was adapted for selection/counter-
selection purpose in recombineering [38]. This technique
takes a similar approach to thyA and galK selection, as aJournal of Biomedicine and Biotechnology 7
ΔtolC background is required for the mutant tolC gene to be
selectable by SDS addition and counterselectable by Colicin
E1 [38]. Again, spontaneous background mutational events
were observed for Colicin E1 selection, warranting the need
to screen potential recombinant colonies [38].
4.5. Recombineering with Single-Stranded Oligos. The excit-
ing potential of recombineering was expanded further when
single-stranded oligonucleotides as short as 30nt were found
to eﬀectively mediate recombinering (Figure 2(h)). Further-
more, this method only requires the Beta [27]o rR e c Tf u n c -
tion [70], with only slight dependence on Gam expression
[27].Interestingly,comparableeﬃcienciesbetweenRecTand
λ Beta in mediating ss-oligos recombineering have been
demonstrated in some work [70], while RecT protein has
been observed to be slightly less eﬃcient than λ Beta in other
[33]. Recombineering is invariably more eﬃcient when the
targeting oligos correspond to the lagging strand in relation
to the replication origin, a phenomenon termed ‘strand
bias’ [27, 70]. This is thought to reﬂect the more abundant
availabilityofexposedssDNAforBetaorRecTbindingatthe
lagging strand during replication [27]. Recombineering by
ss-oligos was taken a step further by using oligos that overlap
as little 6bp to create dsDNA substrates with single-stranded
overhangs [28]( Figure 2(h)). While only Beta is needed
for eﬃcient recombineering of dsDNA with 3  overhangs, a
surprising observation was that when Exo was coexpressed a
higher recombination rate of dsDNA with 5  overhangs was
obtained [28].
5. Applicationsof Recombineering
5.1. BAC-Based Transgenesis. Recombineering has been an
invaluable tool in mouse transgenesis [14]. Because of the
large insert capacity of BACs, the introduced transgenes
are less sensitive to positional eﬀects due to inclusion of
regulatory sequences in the insert [7] and hence eﬀective
in building disease model systems with expression proﬁle
reﬂecting actual pathogenesis. Besides introducing trans-
gene, BACs can also be applied in targeted mutagenesis in
the mouse genome. One excellent demonstration of this
application is the engineering of homozygous knockouts in
mouse embryonic stem (ES) cells [71]( Figure 2(i)). Two
knockout BAC constructs that targeted the same gene were
introduced to mouse ES cells in two rounds of injections,
with targeting eﬃciency ranging from 7% to as high as
28% [71]. More recently, this method was successfully
adapted to create homozygous knockouts in human ES
cells (Figure 2(i)), expanding the applications of transgenesis
BACs from mouse to human model systems [72].
5.2. Linking BACs. The accuracy of recombineering in
manipulating very large DNA molecules makes it a practical
option for joining large DNA fragments to construct big
artiﬁcial chromosomes (Figure 2(j)). This application was
ﬁrst demonstrated in the fusion of two separate but over-
lapping BACs, typically to reconstitute large genes that span
more than one clone into a single recombinant BAC clone
[19, 66, 73]( Figure 2(j)). Following the success of joining
related BACs, Kotzamanis et al. retroﬁtted a ∼70kb-alphoid
DNAintoahumanBACclonesviatheλRedrecombineering
system in an attempt to build human artiﬁcial chromosomes
(HACs) (Figure 2(j)). After transfection, the resulting fusion
minichromosome contained a functional centromere, and
the subcloned gene was expressed correctly [16]. Although
an additional step is needed to assemble a “linker” plasmid
to join the two targets by providing homology sequences, it
is a small price to pay for a universal method to link two or
more unrelated BAC clones [16].
5.3. Virus Mutagenesis and Production. One notable use of
homologous recombination is its successful applications in
manipulation of clinically important viruses (Figure 2(k)).
As virus genomes can reach over 200kb in size (e.g., the
genome size of cytomegalovirus is 235kb), modiﬁcation of
large virus genomes in its entirety poses technical challenges.
However, with the high eﬃciency of recombineering in
manipulating large DNA plasmids, virus genomes can be
subclonedintoanappropriatevectorandessentiallyundergo
engineering as BACs would. Recombinant viruses have been
constructed using conventional homologous recombination
technologies[51,55,56,74],butoverallwithlowereﬃciency
than recombineering. From vaccinia virus [75], herpes
virus [76], to baculovirus [77]( Figure 2(k)), mutagenesis
and production of these viruses were greatly facilitated by
recombineering technologies, as the virus genomes can be
directly modiﬁed on a BAC vector, which can subsequently
serve as the production host once it is transfected into
a suitable cell host for virus reconstitution. This strategy
saves tremendous time and eﬀort, as clonal viruses can
be produced without tedious plaque puriﬁcation procedure
[75].
5.4. Recombineering Pipeline. An important breakthrough
in recombineering application came about when a scalable,
liquid,culture-basedrecombineeringpipelinewasdeveloped
in 2006 for Caenorhabditis elegans [17]( Figure 2(l)). In
just four days, this λ Red-mediated recombineering pipeline
could facilitate EGFP tagging and subcloning of multiple
BAC clones simultaneously [17]. Eﬃciency of the pipeline
was further enhanced when Poser et al. increased the
throughput to 96-well format [78]( Figure 2(l)). Coining
the technology as “BAC TransgeneOmics”, this improved
pipeline enables high-throughput transgenesis method such
as protein tagging in any model system, including mam-
malian cell cultures [78]. Very recently, a specialised recom-
bineering pipeline was developed for generation of speciﬁc
constructs targeting conditional alleles, through a series of
recombineering reactions involving replacement, gap repair,
and insertions [47].
5.5. Recombineering Linear BACs. One novel application of
recombineering developed recently is its use to introduce
structural on top of sequential changes to BACs [79]
(Figure 2(m)). By integrating the telomeric sequences tos of
the linear prophage N15 into a large 100kb BAC construct
followed by appropriate expression of the phage’s telomerase
TelN, the BAC was able to stably replicate as a linear episome8 Journal of Biomedicine and Biotechnology
with resistance to RecBCD exonuclease attack in vivo in E.
coli [79]( Figure 2(m)). After transfer into HeLa cells, this
linear BAC produced accurately spliced β-globin mRNA,
suggesting that this conformation may potentially be useful
as a vector for mammalian gene expression or assembly of
artiﬁcial chromosomes [79].
6. Conclusions andPerspectives
BAC homologous recombination technologies have bene-
ﬁted the research community in ways unimaginable only
decades before. From microbiology, virology to human
genetics, neuroscience, and proteomics, the power to clone
and manipulate large pieces of intact genetic information
with high ﬁdelity has enabled researchers to design and
conduct insightful studies in their respective ﬁelds.
With recombineering being increasingly applied in cre-
ative ways, the only limiting factor for the potential of
recombineering is our imagination. As functional homo-
logues of recombineering enzymes are being discovered in a
broader range of bacteria and their phages [33], more novel
and improved recombineering technologies could be on the
horizon. The use of recombineering functions in non-E. coli
species (e.g.,V i b r i oc h o l e r a[18], Yersinia pseudotuberculosis
[80], and Pseudomonas aeruginosa [81]), as well as the
successful transfers of phage DNA-modifying enzymes (e.g.,
PhiC31 [82]a n dc r e - loxP [83]) from traditional hosts (E.
coli) to mammalian cells are encouraging signs that their
adaptation for use in eukaryotic systems is not too far from
becoming reality.
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